KIMS Board Approves Audited FY26 Results; Appoints Cost Auditors, Senior Management
KIMS Board approved audited FY26 results for the quarter and year ended March 31, 2026. Appointed Sagar & Associates as Cost Auditors for FY27. Identified Sachin Ashok Salvi (CFO), Nagajayanthi J.R (Company Secretary), and Bhaskar Reddy R.K (CRO) as Senior Management Personnel. Re-designated Adwik Bollineni as Executive Director. The 24th AGM will be held on August 27, 2026.
The approval of financial results and key management appointments are material events for stakeholders, influencing investment decisions and corporate governance perception.
The announcement details the approval of financial results, appointments, and re-designations, which are routine corporate actions. While positive for the company, they do not indicate a significant positive or negative shift based solely on this information.
Krishna Institute of Medical Sciences Limited (KIMS) announced the outcome of its Board Meeting held on May 15, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company also appointed M/s. Sagar & Associates as Cost Accountants for FY 2026-27 and recommended their remuneration for member approval at the upcoming AGM. Additionally, KIMS identified three personnel as Senior Management Personnel (SMP) with immediate effect: Mr. Sachin Ashok Salvi as Chief Finance Officer, Mrs. Nagajayanthi J.R as Company Secretary & Compliance Officer, and Mr. Bhaskar Reddy R.K as Chief Risk Officer & Chief Internal Audit. The Board also approved the re-designation of Mr. Adwik Bollineni from Non-Executive & Non-Independent Director to Executive & Non-Independent Director. The 24th Annual General Meeting (AGM) of the Company is scheduled for Thursday, August 27, 2026. The financial results are available on the company's website and the websites of BSE and NSE.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.